| Name | Title | Contact Details |
|---|
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.
Transforming cancer care with data driven medicine
CENTOGENE - transforming genetic data into medical decisions. We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the worlds largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.
ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body`s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.